Post by
ghosttrader on Aug 27, 2009 7:09pm
US FDA go ahead
Interest just keeps growing:
Next piece falls into place
YM BioSciences has obtained special permission from the US government to develop its lead project, nimotuzumab, in the US, expanding its exemption from the economic embargo against Cuba enforced by the Helms-Burton Act. A submission to the US FDA to permit two randomised, double-blind trials to recruit US patients has been made. Nimotuzumab is a potential best-in-class anticancer, and the special licence goes some way to resolving a major risk regarding its development in the US.
Research type: Update - Trading update
The $5.00 target price is looking more realistic everyday, just wait until more good news pours in.